Journal of drugs in dermatology : JDD · 2026
Successful Treatment of Dystrophic Epidermolysis Bullosa With the JAK1 Inhibitor Abrocitinib.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Fang, Zhang Ranran, Fang Ying, Zhou Shan, Dong Jiaming, Han Tingting, Tang Qiaoyue, Wang Yixiao, Zhong Zhenyu, Gao Min
Аннотация
INTRODUCTION: JAK inhibitors are increasingly being utilized for the treatment of diseases beyond their nonclassical indications, and the highly selective JAK1 inhibitor abrocitinib may represent a promising therapeutic option for dystrophic epidermolysis bullosa (DEB).
CASE PRESENTATION: The first case was a 39-year-old male with DEB in whom conventional therapy was ineffective. After one month of abrocitinib treatment, marked improvement in both pruritus and skin lesions was observed, with no adverse drug reactions during six months of therapy. The second case involved a 46-year-old female DEB patient in whom conventional therapy resulted in mild improvement of skin lesions but no significant relief of pruritus.
CONCLUSION: The present two cases provide comparative evidence suggesting the superior efficacy of abrocitinib relative to conventional therapies for DEB.
CASE PRESENTATION: The first case was a 39-year-old male with DEB in whom conventional therapy was ineffective. After one month of abrocitinib treatment, marked improvement in both pruritus and skin lesions was observed, with no adverse drug reactions during six months of therapy. The second case involved a 46-year-old female DEB patient in whom conventional therapy resulted in mild improvement of skin lesions but no significant relief of pruritus.
CONCLUSION: The present two cases provide comparative evidence suggesting the superior efficacy of abrocitinib relative to conventional therapies for DEB.